HTDS Htdsmedical.com (HTDS) The issuer's China based operating subsidiary Mellow Hope through its exclusive business partner Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd has been granted H1N1 license on September 24, 2009 by SFDA (China Authority) Mellow Hope is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd for International marketing and sales

Today, the issuer completed a set of filings in both Chinese and English translations on Pink Sheets Pinksheets.com see filing titled "Supplemental Information - H1N1 License and Supporting Documents" visit website. Also, the company promised in two separate news releases of September 2009 that it will release the name of its exclusive partnership. The filings and supporting H1N1 documents on Pink Sheets are self explanatory.

The company believes that there is a naked short interest in the stock and the company has retained counsel to investigate this matter and possible market manipulation by short sellers. In this connection, the Company has received numerous allegations and complaints from shareholders. In addition, the company has been the victim of anonymous "stock bashing" and a campaign of negative publicity, a smear campaign. In fact, there is a lawsuit in progress on some of these issues.

"We believe that the full potential of our H1N1 vaccine business has yet to be realized in our stock price and this report outlines some of the issues involved," said HTDS CEO Terry Yuan. "Take a good look at all that is going on now for HTDS and you may be surprised to find that when you do so, you share our enthusiasm for HTDS. H1N1 is done and completed so we are eager to start to profit from this huge demand from customers who want to now buy HTDS products immediately. We are also moving with great energy to get our audits completed and get OTCBB listed. When you look at the potential cancer and anti-aging projects of Slavica Bio Chem it is easy to find yourself strongly visualizing their enormous potential. HTDS is also taking aggressive action against the suspected naked shorting that has apparently affected our stock so we can remove all possible barriers to appreciation and give our investors confidence in the future of their investment. Further, most people do not seem to realize we have recently made a sizable recent reduction in our stock outstanding and understand fully what that means. When you add all the excitement all this has created to our eagerness to move forward, it can cause you to start to see that we are on verge of a major expansion. We believe you have to find yourself putting HTDS in that spot in your mind where you would put a company that has virtually unlimited upside. We look forward to the future and we believe that a year from now we will find ourselves looking back on back on this time as one where we all participated in a major expansion."

To receive regular updates on HTDS please sign up or opt in with your email address at the website.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project", and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.